Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients
Clinical Study on Multidimensional Prevention of Sintilimab Induced irAEs Based on GEP Pattern Recognition
Sponsor: Guohui Li
Listed as NCT04840355, this observational or N/A phase trial focuses on Immune Related Adverse Events and PD-1 and remains actively recruiting participants. Sponsored by Guohui Li, it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Jan 2025 — Present [monthly]
Recruiting
Status: Unknown → Recruiting
-
Nov 2024 — Jan 2025 [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2024 — Nov 2024 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
May 2021 — Jul 2024 [monthly]
Recruiting
First recorded
Feb 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Guohui Li
For direct contact, visit the study record on ClinicalTrials.gov .